USFDA gives its nod to IOL chemicals and pharmaceuticals for a plant in Punjab

Published On 2015-07-21 05:56 GMT   |   Update On 2015-07-21 05:56 GMT

IOL chemicals and pharmaceuticals' Barnala based facility will export the drug ibuprofen after receiving an approval from USFDA on a site inspection of the plant


IOL Chemicals and Pharmaceuticals, a Punjab based company has recently achieved a breakthrough in manufacturing its drug, ibuprofen, at a plant in Barnala. The company received the go-ahead after a site inspection conducted by the US Food and Drug Administration.


With this development, IOL can now export a major chunk of ibuprofen to the US, thereby adding significantly to its export turnover. Ibuprofen is a drug used to treat minor aches and pains caused by common cold, headaches, toothaches, back or muscle aches.


The company has received establishment inspection report from the US Food and Drug Administration (USFDA) for the Barnala-based facility, IOLCP said in a filing to the BSE. "Post this approval, IOLCP will be able to garner additional business for its flagship Iburofen in world's largest pharma market--USA," it added.


The Barnala facility has already been approved by various regulatory agencies including Brazil's Anvisa, WHO and MOH, Japan, it added. Shares of IOLCP were trading at Rs 110.20 apiece on the BSE, up 18.75 percent from previous close (as reported by PTI).


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News